Detailed explanation of the efficacy and role of rucaparib/rucaparib

Rucaparib/Rucaparib belongs to a class of drugs called poly-ADP-ribose polymerase (PARP) inhibitors. It is used to treat recurrent ovarian and prostate cancer in adults who have relapsed after previously receiving treatment.

Rucaparib works by inhibitingPARP enzyme activity. PARP enzymes play an important role in DNA repair and help maintain the genome stability of cells. Rucaparib inhibits the activities of three PARP enzymes, PARP-1, PARP-2 and PARP-3. In addition, it interacts with several other PARP enzymes, but to a lesser extent. When rucapanib enters tumor cells, it accumulates and stays in the tumor for a long time, and its effect of inhibiting PARP enzyme can last up to seven days.

Rucaparib's primary mechanism of action is to reduce the growth of tumor cell lines with deficiencies inBRCA1/2 and other DNA repair genes. In addition to inhibiting the function of PARP enzyme, rucapanib also demonstrated PARP-independent cytotoxic effects on cancer cells. Furthermore, rucaparib has shown synergistic or additive effects both in vivo and in vitro when used in combination with other chemotherapeutic agents. There is evidence that rucaparib can increase the sensitivity of cancer cells to chemotherapy drugs.

In addition, rucapanib can induce vasodilation, which may increase tumor perfusion and enhance the accumulation of cytotoxic substances in cancer cells. These effects may help inhibit the growth and spread of cancer cells.

In short, rucapanib is aPARP inhibitor that inhibits tumor growth and increases sensitivity to chemotherapy drugs by interfering with the DNA repair mechanism of cancer cells. Although its indications are mainly for adults with recurrent ovarian cancer and prostate cancer, rucapanib has important potential in the field of tumor treatment and provides patients with new treatment options.